Description

AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–COVID-19-anti-virus–C83H117N23O18S2.xC2HF3O2—Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.|Sci Total Environ. 2024 Mar 13:171681.|Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.-[1]Kajikawa T, et al. Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Mol Ther Methods Clin Dev. 2017 Aug 18;6:207-215.|[2]Mastaglio S, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Apr 29:108450.|[3]Yanyan Liu, et al. Complement C3 Produced by Macrophages Promotes Renal Fibrosis via IL-17A Secretion. Front Immunol. 2018 Oct 22;9:2385.–1789738-04-0–N/A–99.89–C(C(O)=O)(F)(F)F.C(C=1C=2C(N(C)C1)=CC=CC2)[C@H]3C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=4C=5C(NC4)=CC=CC5)C(=O)N(C)CC(=O)N[C@@H](C)C(=O)N[C@@H](CC6=CN=CN6)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(N([C@@H]([C@H](CC)C)C(N)=O)C)=O)CSSC[C@H](NC([C@@H](NC([C@@H](CC7=CC=C(O)C=C7)N)=O)[C@H](CC)C)=O)C(=O)N[C@@H]([C@@H](C)C)C(=O)N3–Inflammation/Immunology–DMSO : ≥ 50 mg/mL|H2O : ≥ 50 mg/mL–Complement System;SARS-CoV—-Anti-infection;Immunology/Inflammation–Peptides